Autres langues Daxor Corporation NYSE

Actions

DXR

US2394671034

Fonds d'investissement à capital fixe

Temps Différé NYSE Autres places de cotation 18:01:26 16/07/2026			Varia. 5j.	Varia. 1 janv.
10,50 ^USD	-0,94%		+0,10%	-28,81%

02/06	Daxor annonce l'obtention d'un brevet américain pour sa technologie de surveillance de la volémie à distance	MT
08/04	Daxor Corporation étend sa base de clients avec un nouveau programme BVA dans un centre de cardiologie à fort volume en Ohio	CI

Autres langues

07/07	Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
02/06	Daxor Says Received US Patent for Remote Blood Volume Monitor Technology
02/06	Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
28/04	Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
27/04	5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026.
08/04	Daxor Corporation Expands Customer Footprint With New BVA Program At High-Volume Ohio Cardiology Center
08/04	Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
26/03	Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
26/03	Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data
17/03	Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26
17/03	Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
10/03	Daxor Corporation Showcases New Portable Blood Volume Analyzer
10/03	Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
09/03	Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
04/03	Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share
03/03	Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders
03/03	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03/03	Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
02/03	Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025
24/02	Daxor Corporation Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
24/02	Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
10/02	Daxor Corp reaffirms focus on blood volume analysis technology
10/02	Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
23/01	Daxor Corporation Announces $9 Million Registered Direct Offering
25/11	Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer